Search

Your search keyword '"Phogat, Sanjay"' showing total 339 results
Start Over Author "Phogat, Sanjay"
339 results on '"Phogat, Sanjay"'

2. Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”

Author

Kibler, Karen V, Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L, Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C, Tomaras, Georgia D, Roederer, Mario, Foulds, Kathryn E, Forthal, Donald N, Seaman, Michael S, Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D, Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, and Jacobs, Bertram L

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Good Health and Well Being, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

Volume 93, no. 3, e01513-18, 2019, https://doi.org/10.1128/JVI.01513-18. The article was originally published on 17 January 2019 with a standard copyright line (“© 2019 American Society for Microbiology. All Rights Reserved.”). We elected to pay for open access for the article after publication, necessitating replacement of the original copyright line with “© 2019 Kibler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.” This change was made to the online version of the article on 21 August 2019.

Published
2019

3. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Author

Kibler, Karen V, Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L, Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C, Tomaras, Georgia D, Roederer, Mario, Foulds, Kathryn E, Forthal, Donald N, Seaman, Michael S, Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D, Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, and Jacobs, Bertram L

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related (AIDS), Biotechnology, Prevention, Immunization, HIV/AIDS, Vaccine Related, Infectious Diseases, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Neutralizing, CD4-Positive T-Lymphocytes, HIV Antibodies, HIV Antigens, HIV Infections, HIV-1, Humans, Macaca mulatta, Male, Vaccination, Vaccinia virus, Viral Vaccines, Virus Replication, env Gene Products, Human Immunodeficiency Virus, Gag-Pol-Nef, HIV, NYVAC, NYVAC-KC, T cell response, antibody responses, gp140, nonhuman primates, vaccines, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia virus strain NYVAC. NYVAC is a vector that has been used in many previous clinical studies but is replication deficient. Here, we report a side-by-side comparison of replication-restricted NYVAC and replication-competent NYVAC-KC in a nonhuman primate study, which utilized a prime-boost regimen similar to that of RV144. NYVAC-C and NYVAC-C-KC express the HIV-1 antigens gp140, and Gag/Gag-Pol-Nef-derived virus-like particles (VLPs) from clade C and were used as the prime, with recombinant virus plus envelope protein used as the boost. In nearly every T and B cell immune assay against HIV-1, including neutralization and antibody binding, NYVAC-C-KC induced a greater immune response than NYVAC-C, indicating that replication competence in a poxvirus may improve upon the modestly successful regimen used in the RV144 clinical trial.IMPORTANCE Though the RV144 phase III clinical trial showed promise that an effective vaccine against HIV-1 is possible, a successful vaccine will require improvement over the vaccine candidate (ALVAC) used in the RV144 study. With that goal in mind, we have tested in nonhuman primates an attenuated but replication-competent vector, NYVAC-KC, in direct comparison to its parental vector, NYVAC, which is replication restricted in human cells, similar to the ALVAC vector used in RV144. We have utilized a prime-boost regimen for administration of the vaccine candidate that is similar to the one used in the RV144 study. The results of this study indicate that a replication-competent poxvirus vector may improve upon the effectiveness of the RV144 clinical trial vaccine candidate.

Published
2019

4. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Author

Asbach, Benedikt, Kibler, Karen V, Köstler, Josef, Perdiguero, Beatriz, Yates, Nicole L, Stanfield-Oakley, Sherry, Tomaras, Georgia D, Kao, Shing-Fen, Foulds, Kathryn E, Roederer, Mario, Seaman, Michael S, Montefiori, David C, Parks, Robert, Ferrari, Guido, Forthal, Donald N, Phogat, Sanjay, Tartaglia, James, Barnett, Susan W, Self, Steven G, Gottardo, Raphael, Cristillo, Anthony D, Weiss, Deborah E, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Esteban, Mariano, Jacobs, Bertram L, Pantaleo, Giuseppe, and Wagner, Ralf

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Prevention, Vaccine Related, HIV/AIDS, Biotechnology, Immunization, Rare Diseases, Vaccine Related (AIDS), Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Neutralizing, HIV Antibodies, HIV Antigens, HIV Infections, HIV-1, Humans, Macaca mulatta, Male, Poxviridae, T-Lymphocytes, Vaccination, Vaccines, DNA, Vaccinia virus, Viral Vaccines, Virus Replication, DNA vaccine, Gag-Pol-Nef, NYVAC, NYVAC-KC, T cell responses, antibody responses, gp140, human immunodeficiency virus, nonhuman primates, vaccine, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different poxvirus boost regimens were compared. Three groups of rhesus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140. The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replication competence in human cells, termed NYVAC-KC. The latter was administered either by scarification or intramuscularly. Finally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses. The regimen elicited very potent CD4+ and CD8+ T cell responses in a well-balanced manner, peaking 2 weeks after the boost. T cells were broadly reactive and polyfunctional. All animals exhibited antigen-specific humoral responses already after the poxvirus boost, which further increased following protein administration. Polyclonal reactivity of IgG antibodies was highest against HIV-1 clade C Env proteins, with considerable cross-reactivity to other clades. Substantial effector functional activities (antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated virus inhibition) were observed in serum obtained after the last protein boost. Notably, major differences between the groups were absent, indicating that the potent priming induced by the DNA vaccine initially framed the immune responses in such a way that the subsequent boosts with NYVAC and protein led only to an increase in the response magnitudes without skewing the quality. This study highlights the importance of selecting the best combination of vector systems in heterologous prime-boost vaccination regimens.IMPORTANCE The evaluation of HIV vaccine efficacy trials indicates that protection would most likely correlate with a polyfunctional immune response involving several effector functions from all arms of the immune system. Heterologous prime-boost regimens have been shown to elicit vigorous T cell and antibody responses in nonhuman primates that, however, qualitatively and quantitatively differ depending on the respective vector systems used. The present study evaluated a DNA prime and poxvirus and protein boost regimen and compared how two poxvirus vectors with various degrees of replication capacity and two different delivery modalities-conventional intramuscular delivery and percutaneous delivery by scarification-impact several immune effectors. It was found that despite the different poxvirus boosts, the overall immune responses in the three groups were similar, suggesting the potent DNA priming as the major determining factor of immune responses. These findings emphasize the importance of selecting optimal priming agents in heterologous prime-boost vaccination settings.

Published
2019

5. Vaccinology in the post−COVID-19 era

Author

Rappuoli, Rino, De Gregorio, Ennio, Del Giudice, Giuseppe, Phogat, Sanjay, Pecetta, Simone, Pizza, Mariagrazia, and Hanon, Emmanuel

Published
2021

6. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

Author

Pitisuthitham, Arom, Sabmee, Yupa, Sirisopana, Narongrid, Eamsila, Chirapa, Savaraj, Prapaporn, Labwech, Wanlaya, Teerachia, Siriluck, Chotirosniramit, Nuntisa, Supindham, Taweewat, Pruenglampoo, Boonlure, Sugandhavesa, Patcharaphan, Kosashunhanan, Natthapol, Kaewthip, Oranitcha, Sroysuwan, Piyathida, Jarujareet, Pawinee, Ratto-Kim, Silvia, Molnar, Sebastian, Schoen, Jesse, Churikanont, Nampueng, Getchalarat, Saowanit, Sangnoi, Nongluck, Nuntapinit, Bessara, Phramtong, Anant, Grandin, Pornsuk V., Madnote, Sirinan, Rittiroongrad, Surawach, Kaewboon, Boot, Trichavaroj, Rapee, Puangkaew, Jiraporn, Chantakulkij, Somsak, Rakyat, Phiromrat, Panjapornsuk, Pornchanok, Tragonlugsana, Nipattra, Chuenarom, Weerawan, de Souza, Mark, Ngauy, Viseth, Phanuphak, Nittaya, Chomchey, Nitiya, Saengtawan, Puttachard, Teeratakulpisarn, Nipat, Rerknimitr, Rungsun, Kroon, Eugene, Lee, Carter A., Chinaworapong, Suchada, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Chariyalertsak, Suwat, Kaewkungwal, Jaranit, Dawson, Peter, Dhitavat, Jittima, Phonrat, Benjaluck, Akapirat, Siriwat, Karasavvas, Nicos, Wieczorek, Lindsay, Polonis, Victoria, Eller, Michael A, Pegu, Poonam, Kim, Dohoon, Schuetz, Alexandra, Jongrakthaitae, Surat, Zhou, Yingjun, Sinangil, Faruk, Phogat, Sanjay, Diazgranados, Carlos A, Tartaglia, James, Heger, Elizabeth, Smith, Kirsten, Michael, Nelson L, Excler, Jean-Louis, Robb, Merlin L, Kim, Jerome H, O'Connell, Robert J, and Vasan, Sandhya

Published
2020
Full Text
View/download PDF

7. Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition

Author

Gordon, Shari N, Liyanage, Namal PM, Doster, Melvin N, Vaccari, Monica, Vargas-Inchaustegui, Diego A, Pegu, Poonam, Schifanella, Luca, Shen, Xiaoying, Tomaras, Georgia D, Rao, Mangala, Billings, Erik A, Schwartz, Jennifer, Prado, Ilia, Bobb, Kathryn, Zhang, Wenlei, Montefiori, David C, Foulds, Kathryn E, Ferrari, Guido, Robert-Guroff, Marjorie, Roederer, Mario, Phan, Tran B, Forthal, Donald N, Stablein, Donald M, Phogat, Sanjay, Venzon, David J, Fouts, Timothy, and Franchini, Genoveffa

Subjects
HIV/AIDS, Vaccine Related (AIDS), Vaccine Related, Prevention, Immunization, Biotechnology, Infectious Diseases, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Infection, Good Health and Well Being, Animals, Antibodies, Viral, CD4 Antigens, Cell Line, Gene Products, env, Macaca mulatta, SAIDS Vaccines, Simian Acquired Immunodeficiency Syndrome, Viral Vaccines, Immunology
Abstract

The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. We hypothesized that the breadth and functional profile of Abs induced by an ALVAC/envelope protein regimen could be improved by substituting the monomeric gp120 boost, with the full-length single-chain (FLSC) protein. FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitopes to the immune system. We compared the immunogenicity and relative efficiency of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum. FLSC was superior to monomeric gp120 in directing Abs to the C3 α2 helix, the V5 loop, and the V3 region that contains the putative CCR5 binding site. In addition, FLSC boosting elicited significantly higher binding Abs to V2 and increased both the Ab-dependent cellular cytotoxicity activity and the breadth of neutralizing Abs. However, the FLSC vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac251 acquisition. In both vaccine regimens, anti-V2 Abs correlated with a decreased risk of virus acquisition but differed with regard to systemic or mucosal origin. In the FLSC regimen, serum Abs to V2 correlated, whereas in the monomeric gp120 regimen, V2 Abs in rectal secretions, the site of viral challenge, were associated with efficacy.

Published
2016

8. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Author

Vaccari, Monica, Gordon, Shari N, Fourati, Slim, Schifanella, Luca, Liyanage, Namal PM, Cameron, Mark, Keele, Brandon F, Shen, Xiaoying, Tomaras, Georgia D, Billings, Erik, Rao, Mangala, Chung, Amy W, Dowell, Karen G, Bailey-Kellogg, Chris, Brown, Eric P, Ackerman, Margaret E, Vargas-Inchaustegui, Diego A, Whitney, Stephen, Doster, Melvin N, Binello, Nicolo, Pegu, Poonam, Montefiori, David C, Foulds, Kathryn, Quinn, David S, Donaldson, Mitzi, Liang, Frank, Loré, Karin, Roederer, Mario, Koup, Richard A, McDermott, Adrian, Ma, Zhong-Min, Miller, Christopher J, Phan, Tran B, Forthal, Donald N, Blackburn, Matthew, Caccuri, Francesca, Bissa, Massimiliano, Ferrari, Guido, Kalyanaraman, Vaniambadi, Ferrari, Maria G, Thompson, DeVon, Robert-Guroff, Marjorie, Ratto-Kim, Silvia, Kim, Jerome H, Michael, Nelson L, Phogat, Sanjay, Barnett, Susan W, Tartaglia, Jim, Venzon, David, Stablein, Donald M, Alter, Galit, Sekaly, Rafick-Pierre, and Franchini, Genoveffa

Subjects
Biomedical and Clinical Sciences, Immunology, Good Health and Well Being, Adaptive Immunity, Adjuvants, Immunologic, Alum Compounds, Animals, Immunity, Innate, Immunity, Mucosal, Immunogenicity, Vaccine, Immunoglobulin G, Interleukin-17, Lymphocytes, Macaca mulatta, Membrane Glycoproteins, Random Allocation, SAIDS Vaccines, Signal Transduction, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Transcriptome, Viral Envelope Proteins, Viral Vaccines, ras Proteins, Simian immunodeficiency virus, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of alum with the more immunogenic MF59 adjuvant is under consideration for the next efficacy human trial. We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an ALVAC-SIV + gp120 MF59 vaccine, was efficacious in delaying the onset of SIVmac251 in rhesus macaques, despite the higher immunogenicity of the latter adjuvant. Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-dependent mucosal innate lymphoid cells (ILCs) that produce interleukin (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 genes, ten of which are part of the RAS pathway. The association between RAS activation and vaccine efficacy was also observed in an independent efficacious SIV-vaccine approach. Whether RAS activation, mucosal ILCs and antibodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.

Published
2016

9. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

Author

Asbach, Benedikt, Kliche, Alexander, Köstler, Josef, Perdiguero, Beatriz, Esteban, Mariano, Jacobs, Bertram L, Montefiori, David C, LaBranche, Celia C, Yates, Nicole L, Tomaras, Georgia D, Ferrari, Guido, Foulds, Kathryn E, Roederer, Mario, Landucci, Gary, Forthal, Donald N, Seaman, Michael S, Hawkins, Natalie, Self, Steven G, Sato, Alicia, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan W, Burke, Brian, Cristillo, Anthony D, Weiss, Deborah E, Francis, Jesse, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L, Pantaleo, Giuseppe, Wagner, Ralf, and Silvestri, G.

Published
2016

10. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection

Author

Dropulic, Lesia K., Oestreich, Makinna C., Pietz, Harlan L., Laing, Kerry J., Hunsberger, Sally, Lumbard, Keith, Garabedian, Doreen, Turk, Siu Ping, Chen, Aiying, Hornung, Ronald L., Seshadri, Chetan, Smith, Malisa T., Hosken, Nancy A., Phogat, Sanjay, Chang, Lee-Jah, Koelle, David M., Wang, Kening, and Cohen, Jeffrey I.

Published
2019

11. Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

Author

Shen, Xiaoying, Duffy, Ryan, Howington, Robert, Cope, Alethea, Sadagopal, Shanmugalakshmi, Park, Haesun, Pal, Ranajit, Kwa, Suefen, Ding, Song, Yang, Otto O, Fouda, Genevieve G, Le Grand, Roger, Bolton, Diane, Esteban, Mariano, Phogat, Sanjay, Roederer, Mario, Amara, Rama R, Picker, Louis J, Seder, Robert A, McElrath, M Juliana, Barnett, Susan, Permar, Sallie R, Shattock, Robin, DeVico, Anthony L, Felber, Barbara K, Pavlakis, George N, Pantaleo, Giuseppe, Korber, Bette T, Montefiori, David C, and Tomaras, Georgia D

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, HIV/AIDS, Sexually Transmitted Infections, Vaccine Related, Biotechnology, Infectious Diseases, Vaccine Related (AIDS), Prevention, Immunization, 3.4 Vaccines, Infection, Good Health and Well Being, Animals, Antibodies, Viral, Antibody Specificity, Epitopes, HIV-1, Immunoglobulin G, Microarray Analysis, Primates, Simian Immunodeficiency Virus, Species Specificity, Viral Envelope Proteins, Simian immunodeficiency virus, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

To evaluate antibody specificities induced by simian immunodeficiency virus (SIV) versus human immunodeficiency virus type 1 (HIV-1) envelope antigens in nonhuman primate (NHP), we profiled binding antibody responses to linear epitopes in NHP studies with HIV-1 or SIV immunogens. We found that, overall, HIV-1 Env IgG responses were dominated by V3, with the notable exception of the responses to the vaccine strain A244 Env that were dominated by V2, whereas the anti-SIVmac239 Env responses were dominated by V2 regardless of the vaccine regimen.

Published
2015

12. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

Author

Bekker, Linda-Gail, Moodie, Zoe, Grunenberg, Nicole, Laher, Fatima, Tomaras, Georgia D, Cohen, Kristen W, Allen, Mary, Malahleha, Mookho, Mngadi, Kathryn, Daniels, Brodie, Innes, Craig, Bentley, Carter, Frahm, Nicole, Morris, Daryl E, Morris, Lynn, Mkhize, Nonhlanhla N, Montefiori, David C, Sarzotti-Kelsoe, Marcella, Grant, Shannon, Yu, Chenchen, Mehra, Vijay L, Pensiero, Michael N, Phogat, Sanjay, DiazGranados, Carlos A, Barnett, Susan W, Kanesa-thasan, Niranjan, Koutsoukos, Marguerite, Michael, Nelson L, Robb, Merlin L, Kublin, James G, Gilbert, Peter B, Corey, Lawrence, Gray, Glenda E, and McElrath, M Juliana

Published
2018
Full Text
View/download PDF

14. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV 144 HIV Vaccine Efficacy Trial

Author

RV305 Study Team, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Excler, Jean-Louis, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Premsri, Nakorn, Kunasol, Prayura, Karasavvas, Nicos, Schuetz, Alexandra, Ngauy, Viseth, Sinangil, Faruk, Dawson, Peter, deCamp, Allan C., Phogat, Sanjay, Garunathan, Sanjay, Tartaglia, James, DiazGranados, Carlos, Ratto-Kim, Silvia, Pegu, Poonam, Eller, Michael, Karnasuta, Chitraporn, Montefiori, David C., Sawant, Sheetal, Vandergrift, Nathan, Wills, Saintedym, Tomaras, Georgia D., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Vasan, Sandhya, and O'Connell, Robert J.

Published
2017

16. HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

Author

Shen, Xiaoying, Laher, Fatima, Moodie, Zoe, McMillan, Arthur S., Spreng, Rachel L., Gilbert, Peter B., Huang, Ying, Yates, Nicole L., Grunenberg, Nicole, Juliana McElrath, M., Allen, Mary, Pensiero, Michael, Mehra, Vijay L., Der Meeren, Olivier Van, Barnett, Susan W., Phogat, Sanjay, Gray, Glenda E., Bekker, Linda-Gail, Corey, Lawrence, and Tomaras, Georgia D.

Published
2020
Full Text
View/download PDF

17. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

Author

Huang, Ying, DiazGranados, Carlos, Janes, Holly, Huang, Yunda, deCamp, Allan C, Metch, Barbara, Grant, Shannon, Sanchez, Brittany, Phogat, Sanjay, Koutsoukos, Marguerite, Kanesa-Thasan, Niranjan, Bourguignon, Patricia, Collard, Alix, Buchbinder, Susan, Tomaras, Georgia D, McElrath, Julie, Gray, Glenda, Kublin, James G, Corey, Lawrence, and Gilbert, Peter B

Published
2016
Full Text
View/download PDF

18. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved

Author

Wiehe, Kevin, Easterhoff, David, Luo, Kan, Nicely, Nathan I., Bradley, Todd, Jaeger, Frederick H., Dennison, S. Moses, Zhang, Ruijun, Lloyd, Krissey E., Stolarchuk, Christina, Parks, Robert, Sutherland, Laura L., Scearce, Richard M., Morris, Lynn, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Sinangil, Faruk, Phogat, Sanjay, Michael, Nelson L., Kim, Jerome H., Kelsoe, Garnett, Montefiori, David C., Tomaras, Georgia D., Bonsignori, Mattia, Santra, Sampa, Kepler, Thomas B., Alam, S. Munir, Moody, M. Anthony, Liao, Hua-Xin, and Haynes, Barton F.

Published
2014
Full Text
View/download PDF

25. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

Author

Bradley, Todd, Pollara, Justin, Santra, Sampa, Vandergrift, Nathan, Pittala, Srivamshi, Bailey-Kellogg, Chris, Shen, Xiaoying, Parks, Robert, Goodman, Derrick, Eaton, Amanda, Balachandran, Harikrishnan, Mach, Linh V., Saunders, Kevin O., Weiner, Joshua A., Scearce, Richard, Sutherland, Laura L., Phogat, Sanjay, Tartaglia, Jim, Reed, Steven G., Hu, Shiu-Lok, Theis, James F., Pinter, Abraham, Montefiori, David C., Kepler, Thomas B., Peachman, Kristina K., Rao, Mangala, Michael, Nelson L., Suscovich, Todd J., Alter, Galit, Ackerman, Margaret E., Moody, M. Anthony, Liao, Hua-Xin, Tomaras, Georgia, Ferrari, Guido, Korber, Bette T., and Haynes, Barton F.

Published
2017
Full Text
View/download PDF

26. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Author

Protocol G. Principal Investigators, Walker, Laura M., Phogat, Sanjay K., Chan-Hui, Po-Ying, Wagner, Denise, Phung, Pham, Goss, Julie L., Wrin, Terri, Simek, Melissa D., Fling, Steven, Mitcham, Jennifer L., Lehrman, Jennifer K., Priddy, Frances H., Olsen, Ole A., Frey, Steven M., Hammond, Phillip W., Kaminsky, Stephen, Zamb, Timothy, Moyle, Matthew, Koff, Wayne C., Poignard, Pascal, and Burton, Dennis R.

Published
2009
Full Text
View/download PDF

28. TMQuery: a database of precomputed template modeling scores for assessment of protein structural similarity

Author

Price, Stephen, primary, Tombeur, Stéphane, additional, Hudson, Alexander, additional, Sathiyamoorthy, Nanda Kumar, additional, Smyth, Paul, additional, Singh, Anjana, additional, Peccianti, Mara, additional, Baroncelli, Elisa, additional, Essaghir, Ahmed, additional, Ferlenghi, Ilaria, additional, Phogat, Sanjay Kumar, additional, and Singh, Gurpreet, additional

Published
2022
Full Text
View/download PDF

31. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Author

McLellan, Jason S., Pancera, Marie, Carrico, Chris, Gorman, Jason, Julien, Jean-Philippe, Khayat, Reza, Louder, Robert, Pejchal, Robert, Sastry, Mallika, Dai, Kaifan, O’Dell, Sijy, Patel, Nikita, Shahzad-ul-Hussan, Syed, Yang, Yongping, Zhang, Baoshan, Zhou, Tongqing, Zhu, Jiang, Boyington, Jeffrey C., Chuang, Gwo-Yu, Diwanji, Devan, Georgiev, Ivelin, Do Kwon, Young, Lee, Doyung, Louder, Mark K., Moquin, Stephanie, Schmidt, Stephen D., Yang, Zhi-Yong, Bonsignori, Mattia, Crump, John A., Kapiga, Saidi H., Sam, Noel E., Haynes, Barton F., Burton, Dennis R., Koff, Wayne C., Walker, Laura M., Phogat, Sanjay, Wyatt, Richard, Orwenyo, Jared, Wang, Lai-Xi, Arthos, James, Bewley, Carole A., Mascola, John R., Nabel, Gary J., Schief, William R., Ward, Andrew B., Wilson, Ian A., and Kwong, Peter D.

Published
2011
Full Text
View/download PDF

32. Broad neutralization coverage of HIV by multiple highly potent antibodies

Author

Walker, Laura M., Huber, Michael, Doores, Katie J., Falkowska, Emilia, Pejchal, Robert, Julien, Jean-Philippe, Wang, Sheng-Kai, Ramos, Alejandra, Chan-Hui, Po-Ying, Moyle, Matthew, Mitcham, Jennifer L., Hammond, Phillip W., Olsen, Ole A., Phung, Pham, Fling, Steven, Wong, Chi-Huey, Phogat, Sanjay, Wrin, Terri, Simek, Melissa D., Koff, Wayne C., Wilson, Ian A., Burton, Dennis R., and Poignard, Pascal

Subjects
HIV antibodies -- Research, Monoclonal antibodies -- Analysis -- Research, AIDS vaccines -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to treat or protect against global circulating viruses. Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies that neutralize broadly across clades. Many of the new monoclonal antibodies are almost tenfold more potent than the recently described PG9, PG16 and VRC01 broadly neutralizing monoclonal antibodies and 100-fold more potent than the original prototype HIV broadly neutralizing monoclonal antibodies (1-3). The monoclonal antibodies largely recapitulate the neutralization breadth found in the corresponding donor serum and many recognize novel epitopes on envelope (Env) glycoprotein gp120, illuminating new targets for vaccine design. Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes. Overall, the isolation of multiple HIV broadly neutralizing monoclonal antibodies from several donors that, in aggregate, provide broad coverage at low concentrations is a highly positive indicator for the eventual design of an effective antibody-based HIV vaccine., Most successful antiviral vaccines elicit neutralizing antibodies as a correlate of protection (4,5). For highly variable viruses--such as HIV, hepatitis C virus (HCV) and, to a lesser extent, influenza--vaccine design [...]

Published
2011
Full Text
View/download PDF

35. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

Author

Gray, Glenda E., primary, Bekker, Linda-Gail, additional, Laher, Fatima, additional, Malahleha, Mookho, additional, Allen, Mary, additional, Moodie, Zoe, additional, Grunenberg, Nicole, additional, Huang, Yunda, additional, Grove, Doug, additional, Prigmore, Brittany, additional, Kee, Jia J., additional, Benkeser, David, additional, Hural, John, additional, Innes, Craig, additional, Lazarus, Erica, additional, Meintjes, Graeme, additional, Naicker, Nivashnee, additional, Kalonji, Dishiki, additional, Nchabeleng, Maphoshane, additional, Sebe, Modulakgotla, additional, Singh, Nishanta, additional, Kotze, Philip, additional, Kassim, Sheetal, additional, Dubula, Thozama, additional, Naicker, Vimla, additional, Brumskine, William, additional, Ncayiya, Cleon N., additional, Ward, Amy M., additional, Garrett, Nigel, additional, Kistnasami, Girisha, additional, Gaffoor, Zakir, additional, Selepe, Pearl, additional, Makhoba, Philisiwe B., additional, Mathebula, Matsontso P., additional, Mda, Pamela, additional, Adonis, Tania, additional, Mapetla, Katlego S., additional, Modibedi, Bontle, additional, Philip, Tricia, additional, Kobane, Gladys, additional, Bentley, Carter, additional, Ramirez, Shelly, additional, Takuva, Simbarashe, additional, Jones, Megan, additional, Sikhosana, Mpho, additional, Atujuna, Millicent, additional, Andrasik, Michele, additional, Hejazi, Nima S., additional, Puren, Adrian, additional, Wiesner, Lubbe, additional, Phogat, Sanjay, additional, Diaz Granados, Carlos, additional, Koutsoukos, Marguerite, additional, Van Der Meeren, Olivier, additional, Barnett, Susan W., additional, Kanesa-Thasan, Niranjan, additional, Kublin, James G., additional, McElrath, M. Juliana, additional, Gilbert, Peter B., additional, Janes, Holly, additional, and Corey, Lawrence, additional

Published
2021
Full Text
View/download PDF

36. Structural basis of tyrosine sulfation and [V.sub.H]-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

Author

Huang, Chih-chin, Venturi, Miro, Majeed, Shahzad, Moore, Michael J., Phogat, Sanjay, Zhang, Mei-Yun, Dimitrov, Dimiter S., Hendrickson, Wayne A., Robinson, James, Sodroski, Joseph, Wyatt, Richard, Choe, Hyeryun, Farzan, Michael, and Kwong, Peter D.

Subjects
Tyrosine -- Research, Science and technology
Abstract

The conserved surface of the HIV-1 gp120 envelope glycoprotein that binds to the HIV-1 coreceptor is protected from humoral recognition by multiple layers of camouflage. Here we present sequence and genomic analyses for 12 antibodies that pierce these defenses and determine the crystal structures of 5. The data reveal mechanisms and atomic-level details for three unusual immune features: posttranslational mimicry of coreceptor by tyrosine sulfation of antibody, an alternative molecular mechanism controlling such sulfation, and highly selective [V.sub.H]-gene usage. When confronted by extraordinary viral defenses, the immune system unveils novel adaptive capabilities, with tyrosine sulfation enhancing the vocabulary of antigen recognition.

Published
2004

37. Comparative analysis of 10 small molecules binding to carbonic anhydrase II by different investigators using Biacore technology

Author

Papalia, Giuseppe A., Leavitt, Stephanie, Bynum, Maggie A., Katsamba, Phinikoula S., Wilton, Rosemarie, Qiu, Huawei, Steukers, Mieke, Wang, Siming, Bindu, Lakshman, Phogat, Sanjay, Giannetti, Anthony M., Ryan, Thomas E., Pudlak, Victoria A., Matusiewicz, Katarzyna, Michelson, Klaus M., Nowakowski, Agnes, Pham-Baginski, Anh, Brooks, Jonathan, Tieman, Bryan C., Bruce, Barry D., Vaughn, Michael, Baksh, Michael, Cho, Yun Hee, Wit, Mieke De, Smets, Alexandra, Vandersmissen, Johan, Michiels, Lieve, and Myszka, David G.

Published
2006
Full Text
View/download PDF

40. Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens

Author

Chow, Yen-Hung, Wei, Olivia l., Phogat, Sanjay, Sidorov, Igor A., Fouts, Timothy R., Broder, Christopher C., and Dimitrov, Dimiter S.

Subjects
HIV (Viruses) -- Receptors, Glycoproteins -- Physiological aspects, Binding sites (Biochemistry) -- Analysis, Viruses, Biological sciences, Chemistry
Abstract

Research reveals that gp120-linker-gp41 proteins are inhibitory of fusion and entry of many HIV-1 isolates. The inhibition is mediated by the exposed conserved gp41 structures, which can block the entry process. Implication of this finding is discussed with reference to gp41 structures utility in the development of HIV-1 inhibitors and vaccine immunogens.

Published
2002

41. Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

Author

Schifanella, Luca, primary, Barnett, Susan W., additional, Bissa, Massimiliano, additional, Galli, Veronica, additional, Doster, Melvin N., additional, Vaccari, Monica, additional, Tomaras, Georgia D., additional, Shen, Xiaoying, additional, Phogat, Sanjay, additional, Pal, Ranajit, additional, Montefiori, David C., additional, LaBranche, Celia C., additional, Rao, Mangala, additional, Trinh, Hung V., additional, Washington-Parks, Robyn, additional, Liyanage, Namal P. M., additional, Gorini, Giacomo, additional, Brown, Dallas R., additional, Liang, Frank, additional, Loré, Karin, additional, Venzon, David J., additional, Magnanelli, William, additional, Metrinko, Michelle, additional, Kramer, Josh, additional, Breed, Matthew, additional, Alter, Galit, additional, Ruprecht, Ruth M., additional, and Franchini, Genoveffa, additional

Published
2020
Full Text
View/download PDF

42. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

Author

Pitisuttithum, Punnee, primary, Nitayaphan, Sorachai, additional, Chariyalertsak, Suwat, additional, Kaewkungwal, Jaranit, additional, Dawson, Peter, additional, Dhitavat, Jittima, additional, Phonrat, Benjaluck, additional, Akapirat, Siriwat, additional, Karasavvas, Nicos, additional, Wieczorek, Lindsay, additional, Polonis, Victoria, additional, Eller, Michael A, additional, Pegu, Poonam, additional, Kim, Dohoon, additional, Schuetz, Alexandra, additional, Jongrakthaitae, Surat, additional, Zhou, Yingjun, additional, Sinangil, Faruk, additional, Phogat, Sanjay, additional, Diazgranados, Carlos A, additional, Tartaglia, James, additional, Heger, Elizabeth, additional, Smith, Kirsten, additional, Michael, Nelson L, additional, Excler, Jean-Louis, additional, Robb, Merlin L, additional, Kim, Jerome H, additional, O'Connell, Robert J, additional, Vasan, Sandhya, additional, Pitisuthitham, Arom, additional, Sabmee, Yupa, additional, Sirisopana, Narongrid, additional, Eamsila, Chirapa, additional, Savaraj, Prapaporn, additional, Labwech, Wanlaya, additional, Teerachia, Siriluck, additional, Chotirosniramit, Nuntisa, additional, Supindham, Taweewat, additional, Pruenglampoo, Boonlure, additional, Sugandhavesa, Patcharaphan, additional, Kosashunhanan, Natthapol, additional, Kaewthip, Oranitcha, additional, Sroysuwan, Piyathida, additional, Jarujareet, Pawinee, additional, Ratto-Kim, Silvia, additional, Molnar, Sebastian, additional, Schoen, Jesse, additional, Churikanont, Nampueng, additional, Getchalarat, Saowanit, additional, Sangnoi, Nongluck, additional, Nuntapinit, Bessara, additional, Phramtong, Anant, additional, Grandin, Pornsuk V., additional, Madnote, Sirinan, additional, Rittiroongrad, Surawach, additional, Kaewboon, Boot, additional, Trichavaroj, Rapee, additional, Puangkaew, Jiraporn, additional, Chantakulkij, Somsak, additional, Rakyat, Phiromrat, additional, Panjapornsuk, Pornchanok, additional, Tragonlugsana, Nipattra, additional, Chuenarom, Weerawan, additional, de Souza, Mark, additional, Ngauy, Viseth, additional, Phanuphak, Nittaya, additional, Chomchey, Nitiya, additional, Saengtawan, Puttachard, additional, Teeratakulpisarn, Nipat, additional, Rerknimitr, Rungsun, additional, Kroon, Eugene, additional, Lee, Carter A., additional, and Chinaworapong, Suchada, additional

Published
2020
Full Text
View/download PDF

43. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Author

Laher, Fatima, primary, Moodie, Zoe, additional, Cohen, Kristen W., additional, Grunenberg, Nicole, additional, Bekker, Linda-Gail, additional, Allen, Mary, additional, Frahm, Nicole, additional, Yates, Nicole L., additional, Morris, Lynn, additional, Malahleha, Mookho, additional, Mngadi, Kathryn, additional, Daniels, Brodie, additional, Innes, Craig, additional, Saunders, Kevin, additional, Grant, Shannon, additional, Yu, Chenchen, additional, Gilbert, Peter B., additional, Phogat, Sanjay, additional, DiazGranados, Carlos A., additional, Koutsoukos, Marguerite, additional, Van Der Meeren, Olivier, additional, Bentley, Carter, additional, Mkhize, Nonhlanhla N., additional, Pensiero, Michael N., additional, Mehra, Vijay L., additional, Kublin, James G., additional, Corey, Lawrence, additional, Montefiori, David C., additional, Gray, Glenda E., additional, McElrath, M. Juliana, additional, and Tomaras, Georgia D., additional

Published
2020
Full Text
View/download PDF

45. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Author

Walker, Laura M., Phogat, Sanjay K., Chan-Hui, Po-Ying, Wagner, Denise, Phung, Pham, Goss, Julie L, Wrin, Terri, Simek, Melissa D., Fling, Steven, Mitcham, Jennifer L, Lehrman, Jennifer K., Priddy, Frances H., Olsen, Ole A., Frey, Steven M., Hammond, Phillip W., Principal Investigators, Protocol G, Kaminsky, Stephen, Zamb, Timothy, Moyle, Matthew, Koff, Wayne C., Poignard, Pascal, and Burton, Dennis R.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results